{"url_path":"/sec/exoz/8-k/2026-06-26/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/2010788/0001493152-26-030205-index.html","accession_number":"0001493152-26-030205","cik":"0002010788","ticker":"EXOZ","issuer_name":"EXOZYMES INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2010788/0001493152-26-030205-index.html","primary_entity_key":"0002010788","primary_entity_name":"EXOZYMES INC."},"word_count":91,"has_tables":true,"body_markdown":"**Item 7.01**\n**Regulation FD Disclosure**\n\n \n\nOn\nJune 24, 2026, the Company issued a press release announcing that it was being awarded a $2 Million NIH grant to advance cannaboinoid\nanalogs for drug discovery.\n\n \n\nThe\ninformation contained in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange\nAct of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act, or the\nExchange Act, except as shall be expressly set forth by specific reference in such a filing."}